SUBSEQUENT EVENTS	6 Months Ended
Jun. 30, 2016
Notes to Financial Statements
Note 8 - SUBSEQUENT EVENTS	On August 4, 2016, the Company's wholly owned subsidiary Sky Pharm S.A. ("Sky Pharm") entered into a Loan Facility Agreement, guaranteed by Grigorios Siokas, with Synthesis Peer-To Peer-Income Fund (the "Loan Facility"). The Loan Facility provides Sky Pharm with a credit facility of up to $1,292,769. Any advance under the Loan Facility accrues interest at a rate of 10% per annum and requires quarterly interest payments commencing on September 30, 2016. The amounts owed under the Loan Facility shall be repayable upon the earlier of (i) three months following the demand of the lender; or (ii) August 31, 2018. No prepayment is permitted pursuant to the terms of the Loan Facility. The Synthesis Facility Agreement is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 10,000,000 shares of common stock of the Company owned by Mr. Siokas. As of the date hereof the Company has taken an advance of $1,292,769.

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2016

On August 4, 2016, the Company's wholly owned subsidiary Sky Pharm S.A. ("Sky Pharm") entered into a Loan Facility Agreement, guaranteed by Grigorios Siokas, with Synthesis Peer-To Peer-Income Fund (the "Loan Facility"). The Loan Facility provides Sky Pharm with a credit facility of up to $1,292,769. Any advance under the Loan Facility accrues interest at a rate of 10% per annum and requires quarterly interest payments commencing on September 30, 2016. The amounts owed under the Loan Facility shall be repayable upon the earlier of (i) three months following the demand of the lender; or (ii) August 31, 2018. No prepayment is permitted pursuant to the terms of the Loan Facility. The Synthesis Facility Agreement is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 10,000,000 shares of common stock of the Company owned by Mr. Siokas. As of the date hereof the Company has taken an advance of $1,292,769.